CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $7.47M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 7.78: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.71BUSDvs all stocks (USD)
Revenue (TTM)
7.47MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.16xvs all stocks
52-Week Change
135.57%vs all stocks
Market Capitalization
1.71BUSDvs all stocks (USD)
Enterprise Value
1.50BUSDvs all stocks (USD)
Forward P/E
-13.70xvs Biotechnology peers
Price to Book (MRQ)
8.08xvs Biotechnology peers
Enterprise to Revenue
201.40xvs Biotechnology peers
Enterprise to EBITDA
-11.45xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1774.37%vs Biotechnology peers
Return on Assets (TTM)
-37.77%vs Biotechnology peers
Return on Equity (TTM)
-97.28%vs Biotechnology peers
Revenue (TTM)
7.47MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0220USDUpdated Jul 19, 2026Quarterly Revenue Growth
-100.00%vs Biotechnology peers
Gross Profit (TTM)
7.47MUSDvs all stocks (USD)
EBITDA (TTM)
-131.41MUSDvs all stocks (USD)
Net Income (TTM)
-129.88MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-111.95MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-73.45MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
9.77MUSDFY2025 · Dec 31, 2025Operating Income
-110.50MUSDvs all stocks (USD)
Pre-tax Income
-109.00MUSDFY2025 · Dec 31, 2025Net Income
-109.00MUSDFY2025 · Dec 31, 2025EBIT
-108.93MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-106.59MUSDFY2025 · Dec 31, 2025Research & Development
86.40MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
33.87MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.22MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
63.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-109.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-98.84MUSDFY2025 · Dec 31, 2025Free Cash Flow
-99.58MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
322.53MUSDFY2025 · Dec 31, 2025Interest Paid
5.40MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-109.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.15MUSDFY2025 · Dec 31, 2025Stock-based Compensation
13.30MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.63MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-153.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.77MUSDFY2025 · Dec 31, 2025Capital Expenditures
-738.00KUSDFY2025 · Dec 31, 2025Other Investing Activity
134.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-604.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
49.85MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-40.61MUSDFY2025 · Dec 31, 2025Other Financing Charges
-337.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
273.21MUSDFY2025 · Dec 31, 2025Shares Outstanding
287.28MSharesUpdated Jul 19, 2026Float Shares
205.97MSharesUpdated Jul 19, 2026Shares Short
41.40MSharesUpdated Jul 19, 2026Short Ratio
10.84daysvs all stocks
Short % of Shares Outstanding
14.67%vs all stocks
% Held by Insiders
9.63%vs all stocks
% Held by Institutions
86.20%vs all stocks
Total Cash (MRQ)
276.58MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.9620USDUpdated Jul 19, 2026Total Debt (MRQ)
68.55MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3234xvs Biotechnology peers
Current Ratio (MRQ)
14.04xvs Biotechnology peers
Book Value per Share (MRQ)
0.7380USDUpdated Jul 19, 2026Total Assets
343.32MUSDvs all stocks (USD)
Total Current Assets
324.65MUSDFY2025 · Dec 31, 2025Total Liabilities
96.38MUSDFY2025 · Dec 31, 2025Total Non-current Assets
18.67MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
69.83MUSDFY2025 · Dec 31, 2025Total Current Liabilities
26.55MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
319.77MUSDFY2025 · Dec 31, 2025Accounts Payable
6.28MUSDFY2025 · Dec 31, 2025Short-term Debt
1.86MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
777.00KUSDFY2025 · Dec 31, 2025Long-term Debt
68.28MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.55MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-711.30MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
246.94MUSDvs all stocks (USD)
52-Week Low
2.34USDUpdated Jul 19, 202652-Week High
7.30USDUpdated Jul 19, 202652-Week Change
135.57%vs all stocks
Beta
1.16xvs all stocks
50-Day MA
6.10USDUpdated Jul 19, 2026200-Day MA
5.20USDUpdated Jul 19, 2026Avg 10-Day Volume
3.60MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.89MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.3800USDUpdated Jul 19, 2026Other Income / Expense
-7.66MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 7.78: safe zoneNotable
Altman Z-Score: 7.78
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $7.47M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,471,000Global P5: 30,274,777.221
Market cap is $1.71B, above the global median of $1.15BNotable
Market cap (USD): 1,712,671,679Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cofoe Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Butterfly Network Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Aeva Technologies, Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Immunome Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Inhibikase Therapeutics Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets